Affymetrix & Leica Microsystems Announce Worldwide Collaboration on Automated, Single-Copy, RNA In Situ Hybridization (ISH) T...
May 31 2012 - 7:30AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) and Leica Microsystems are
pleased to announce a world-wide collaboration that automates
Affymetrix’ QuantiGene® ViewRNA ISH Tissue Assay on the Leica
BOND RX staining platform for research applications*. This
partnership provides researchers with a powerful automated everyday
solution for drug-discovery, translational research, and the
development of new companion diagnostic tests for personalized
medicine by significantly reducing assay time for single-copy RNA
in situ hybridization (ISH) analysis.
The highly-sensitive QuantiGene® ViewRNA ISH Tissue Assay
assists drug discovery and translation research by enabling
researchers to measure RNA expression directly in a tissue section
at single-copy sensitivity. Over one thousand standard probes are
already available and it only takes a few days to produce a
customized probe for a new gene target. The Leica BOND RX
system automates the staining process bringing all the benefits of
consistency, reduced labor, and speed. This means researchers can
now have access to same-day assay completion and, with a
standardized staining protocol, rapid set-up for any probe.
George Bers, Vice President and General Manager of Expression
Business Unit - Panomics at Affymetrix states that: “We are excited
by this partnership with Leica as it unlocks the true potential of
single-copy RNA analysis and we believe it will accelerate the
discovery of important new drugs and the validation of novel
companion tests.”
Arnd Kaldowski, President of Leica Biosystems, agrees saying
“While medical science has created powerful new treatments that
greatly enhance lives, there are still many disease states where we
need to discover better treatments, or even cures. We are proud
that this collaboration with Affymetrix can help in the discovery
and development process by enabling researchers to reduce both the
time and cost of research so that new treatments can be made
available to patients sooner.”
Affymetrix’ QuantiGene® ViewRNA ISH Tissue Assay will be
available for research applications in Q3 2012 on the
research-optimized Leica BOND RX platform. An optimized
QuantiGene® ViewRNA staining protocol will be pre-loaded onto the
Leica BOND RX and a complete staining kit, including probes
and all detection components, will be available from
Affymetrix.
*For Research Use Only. Not for use in diagnostic
procedures.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip,
QuantiGene and all other trademarks are the property of Affymetrix,
Inc. All other trademarks are the property of their respective
owners.
About Leica Microsystems
Leica Microsystems is a world leader in microscopes and
scientific instruments. Founded as a family business in the
nineteenth century, the company’s history was marked by
unparalleled innovation on its way to becoming a global
enterprise.
Its historically close cooperation with the scientific community
is the key to Leica Microsystems’ tradition of innovation, which
draws on users’ ideas and creates solutions tailored to their
requirements. At the global level, Leica Microsystems is organized
in four divisions, all of which are among the leaders in their
respective fields: the Life Science Division, Industry Division,
Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica
Biosystems, offers histopathology laboratories the most extensive
product range with appropriate products for each work step in
histology and for a high level of productivity in the working
processes of the entire laboratory.
The company is represented in over 100 countries with 12
manufacturing facilities in 7 countries, sales and service
organizations in 19 countries and an international network of
dealers. The company is headquartered in Wetzlar, Germany.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
25,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Asia,
and Latin America. For more information about Affymetrix, please
visit http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip,
QuantiGene and all other trademarks are the property of Affymetrix,
Inc. All other trademarks are the property of their respective
owners.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024